Crispr Therapeutics Ag Stock Current Valuation
| CRSP Stock | USD 53.74 0.32 0.59% |
Valuation analysis of Crispr Therapeutics helps investors to measure Crispr Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 06/01/2024, Enterprise Value Over EBITDA is likely to grow to -22.54. In addition to that, Enterprise Value Multiple is likely to grow to -22.54. Fundamental drivers impacting Crispr Therapeutics' valuation include:
Price Book 2.7352 | Enterprise Value 2.7 B | Enterprise Value Ebitda (18.23) | Price Sales 13.8733 | Forward PE 23.3645 |
Undervalued
Today
Please note that Crispr Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Crispr Therapeutics is based on 3 months time horizon. Increasing Crispr Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Crispr Therapeutics AG is useful when determining the fair value of the Crispr stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Crispr Therapeutics. Since Crispr Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Crispr Stock. However, Crispr Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 53.74 | Real 69.05 | Target 88.13 | Hype 52.9 | Naive 50.45 |
The real value of Crispr Stock, also known as its intrinsic value, is the underlying worth of Crispr Therapeutics Company, which is reflected in its stock price. It is based on Crispr Therapeutics' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Crispr Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Crispr Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Crispr Therapeutics AG helps investors to forecast how Crispr stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Crispr Therapeutics more accurately as focusing exclusively on Crispr Therapeutics' fundamentals will not take into account other important factors: Crispr Therapeutics AG Company Current Valuation Analysis
Crispr Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Crispr Therapeutics Current Valuation | 2.72 B |
Most of Crispr Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Crispr Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Crispr Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Crispr Therapeutics is extremely important. It helps to project a fair market value of Crispr Stock properly, considering its historical fundamentals such as Current Valuation. Since Crispr Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Crispr Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Crispr Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Crispr Therapeutics AG has a Current Valuation of 2.72 B. This is 81.08% lower than that of the Biotechnology sector and 41.5% lower than that of the Health Care industry. The current valuation for all United States stocks is 83.65% higher than that of the company.
Crispr Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Crispr Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Crispr Therapeutics could also be used in its relative valuation, which is a method of valuing Crispr Therapeutics by comparing valuation metrics of similar companies.Crispr Therapeutics is currently under evaluation in current valuation category among related companies.
Crispr Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Crispr Therapeutics from analyzing Crispr Therapeutics' financial statements. These drivers represent accounts that assess Crispr Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Crispr Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 3.3B | 10.1B | 5.8B | 3.2B | 2.8B | 2.3B | |
| Enterprise Value | 2.4B | 9.0B | 5.1B | 3.2B | 2.9B | 1.9B |
Crispr Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Crispr Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Crispr Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Crispr Fundamentals
| Return On Equity | -0.11 | ||||
| Return On Asset | -0.0797 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (278.94) % | ||||
| Current Valuation | 2.72 B | ||||
| Shares Outstanding | 84.92 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 71.19 % | ||||
| Number Of Shares Shorted | 15.33 M | ||||
| Price To Earning | 17.33 X | ||||
| Price To Book | 2.74 X | ||||
| Price To Sales | 13.87 X | ||||
| Revenue | 370 M | ||||
| Gross Profit | (570.7 M) | ||||
| EBITDA | (202.7 M) | ||||
| Net Income | (153.61 M) | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 26.48 X | ||||
| Total Debt | 238.63 M | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 17.57 X | ||||
| Book Value Per Share | 24.56 X | ||||
| Cash Flow From Operations | (260.38 M) | ||||
| Short Ratio | 10.63 X | ||||
| Earnings Per Share | (2.70) X | ||||
| Price To Earnings To Growth | (0.21) X | ||||
| Target Price | 84.29 | ||||
| Number Of Employees | 407 | ||||
| Beta | 1.79 | ||||
| Market Capitalization | 4.57 B | ||||
| Total Asset | 2.23 B | ||||
| Retained Earnings | (999.7 M) | ||||
| Working Capital | 1.8 B | ||||
| Current Asset | 232 M | ||||
| Current Liabilities | 78 M | ||||
| Net Asset | 2.23 B |
About Crispr Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Crispr Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Crispr Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Crispr Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Crispr Therapeutics Piotroski F Score and Crispr Therapeutics Altman Z Score analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.70) | Revenue Per Share 3.396 | Quarterly Revenue Growth (0.99) | Return On Assets (0.08) | Return On Equity (0.11) |
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.